Other News To Note
Tuesday, October 8, 2013
• Debiopharm Group, of Lausanne, Switzerland, signed an exclusive research collaboration with the Experimental Therapeutics Centre at Singapore’s Agency for Science, Technology and Research to develop oral small molecules targeting tumors with genetic lesions.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.